Soft tissue metastasis from carcinomas or sarcomas is extremely rare. These tumors can arise from different cancer types, including renal, lung, other adenocarcinoma tumors, and even sarcomas. Distinguishing between primary soft tissue sarcoma and metastatic carcinoma is quite challenging because it could change their prognosis. The prevalence of soft tissue metastasis is around 16–17.5% in autopsy reports. However, in clinical practice, it could be as low as less than 1.8%. These soft tissue metastases are often indicative of advanced disease, with survival rates around 33% at two years. Metastases in target organs such as the brain, lungs, and bones can make this prognosis even worse. Therefore, conducting thorough evaluations for these patients is crucial, including diagnostic tests, staging, survival analysis, different treatment options, and palliative care. Early diagnosis may have a positive impact in survival, and surgical treatment can help in local control and pain relief, which will improve the patient’s quality of life.